STOCKS TELEGRAPH

Tag: MeiraGTx Stock

  • MeiraGTx (MGTX) Stock Climbs in Pre-Hour Trading

    MeiraGTx (MGTX) Stock Climbs in Pre-Hour Trading

    The stock value of MeiraGTx Holdings plc (NASDAQ: MGTX) has increased significantly after the company’s financial results were made public and a strategic partnership was announced. The shares of MGTX were up 17% at $7.50 as of the most recent pre-market check.

    Strong Market Response to Financial Results

    Along with significant business accomplishments, MeiraGTx revealed its financial and operational results for the fourth quarter and full year ended December 31, 2024. As of December 31, 2024, MeiraGTx reported $105.7 million in cash, cash equivalents, and restricted cash holdings, down from $130.6 million at the end of the prior year.

    Due to advancements in process performance qualification services under the asset acquisition agreement with Johnson & Johnson Innovative Medicine, the business additionally reported $33.3 million in service revenue for 2024. For 2023, no service income has been reported.

    Leading the Way in AI-Powered Drug Development

    MeiraGTx has engaged into a strategic partnership with Hologen, a top creator of multi-modal generative AI foundation models, in a ground-breaking step for 2025. Two components of the collaboration include the creation of a joint venture, Hologen Neuro AI Ltd., backed by an additional $230 million in pledged capital, and a $200 million upfront cash payment to MeiraGTx.

    The collaborative venture aims to increase the efficacy and success rate of the AAV-GAD Phase 3 clinical study for Parkinson’s disease by applying AI-driven insights. Hologen’s AI technology has already demonstrated promise by identifying disease-modifying physiological changes in the brain and de-risking MeiraGTx’s AAV-GAD program.

    The partnership seeks to revolutionize the treatment of neuropsychiatric and neurodegenerative diseases by fusing cutting-edge AI with MeiraGTx’s knowledge of gene therapy.

    Changing the Way CNS Drugs Are Found

    The founding of Hologen Neuro AI Ltd. represents a significant step toward clinical medication development with AI integration. Treatments that target the central nervous system (CNS) circuitry will be developed using Hologen’s AI capabilities and MeiraGTx’s gene therapy innovations. Neuropsychiatric and neurodegenerative disorders that have so far eluded effective treatment may benefit from this collaboration.

  • MeiraGTx (MGTX) Sees Stock Surge Following Promising Clinical Study Results

    MeiraGTx (MGTX) Sees Stock Surge Following Promising Clinical Study Results

    Following the release of encouraging findings from its clinical research, shares of MeiraGTx Holdings plc (NASDAQ: MGTX) have seen a significant boost, reaching $5.25, or 13.15%, in value. Top-line data from the company’s clinical bridging trial, MGT-GAD-025, which focused on AAV-GAD as a possible Parkinson’s disease therapy, was released.

    Promising Safety and Efficacy Results

    The safety and efficacy outcomes reported by MeiraGTx (MSTX) are particularly encouraging. Notably, motor scores and quality of life significantly improved for individuals undergoing the high-dose therapy. Both patients and medical professionals stand to benefit greatly from these advancements.

    The clinical data, derived from material produced using MGTX’s proprietary commercial platform process, indicate that AAV-GAD is safe across all dosage levels studied, including higher doses not previously tested. To date, MeiraGTx has treated a total of 58 patients across three independent multicenter clinical trials, with no serious adverse events associated with AAV-GAD treatment.

    Significant Clinical Impact

    With the completion of this randomized, double-blind bridging study, MeiraGTx has demonstrated that AAV-GAD treatment leads to substantial and clinically meaningful changes in key efficacy endpoints for Parkinson’s disease. A change of 5 to 10 points in UPDRS Part 3 is considered clinically significant, and the observed 18-point improvement in the high-dose group underscores the treatment’s potential impact.

    Similarly, for the PDQ-39 assessment, the changes of 8 points in the high-dose group and 6 points in the low-dose group further emphasize the treatment’s effectiveness.

    Path Forward for Global Approval

    The findings highlight the potential of targeted local delivery of gene-based therapy to address the dopamine depletion characteristic of idiopathic Parkinson’s disease. AAV-GAD treatment aims to normalize circuit function across various forms of the disease.

    The significant clinical improvements observed in this study provide MeiraGTx with a clear path forward in its clinical development strategy, bolstering discussions with regulatory authorities in the U.S., Europe, and Japan to initiate a Phase 3 study aimed at global approval of this disease-modifying therapy.

  • MeiraGTx (MGTX) Is Rising Winning A Strategic Investment

    MeiraGTx (MGTX) Is Rising Winning A Strategic Investment

    MeiraGTx Holdings Plc (NASDAQ: MGTX) shares are experiencing an upward trajectory on the stock market today. In the morning session, MeiraGTx’s stock displayed a notable surge of 26.76%, reaching $4.69 at the last check. This positive trend in MGTX’s stock value is attributed to the company’s recent announcement of securing a strategic investment.

    MeiraGTx (MGTX) stands as a vertically integrated, clinical-stage gene therapy enterprise. MGTX has officially disclosed strategic developments, with the noteworthy revelation that Sanofi has injected $30 million into the company through the acquisition of 4.0 million ordinary shares, each priced at $7.50 per share.

    This substantial financial involvement represents Sanofi’s maiden foray into strategic investments with MeiraGTx. It is noteworthy that MeiraGTx perceives Sanofi’s keen interest in its Riboswitch gene regulation technology, alongside a parallel enthusiasm for MGTX’s clinical Xerostomia program, which serves as further validation of the comprehensive capabilities inherent in their vertically integrated platform.

    MeiraGTx has unequivocally committed to collaborating closely with Sanofi as they advance these programs. Sanofi, a stalwart in the quest for pioneering medicines and vaccines, maintains an open-minded approach toward technological innovations that can facilitate their pursuit of future scientific advancements.

    The Riboswitch platform offered by MeiraGTx, bolstered by its distinctive manufacturing prowess, represents precisely the type of innovation Sanofi seeks. This collaborative effort between Sanofi and MeiraGTx is poised to usher in a new era of groundbreaking medications tailored to address immune-mediated and neurological diseases.

    MeiraGTx, with its extensive expertise in genetic medicines, boasts late-stage clinical initiatives, world-class end-to-end manufacturing capabilities, and a revolutionary Riboswitch gene regulation technology. In light of the considerable interest expressed by various parties over recent months, all keen on exploring mutually advantageous strategic transactions related to certain assets of the company, Sanofi has enlisted the services of Evercore and Wachtell Lipton to collaborate with MeiraGTx’s management and Board of Directors in the execution of one or more of these potential strategic transactions.